Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Expert Opinion on Emerging Drugs|December 3, 2008
Parkinson's disease: emerging pharmacotherapyKarl Strecker, Johannes SchwarzScientific Reports|April 4, 2020
Compensating Atmospheric Channel Dispersion for Terahertz Wireless CommunicationKarl Strecker, Sabit Ekin, John F O'HaraNeurosurgery|December 6, 2008
Increase of frequency in deep brain stimulation relieves apraxia of eyelid opening in patients with Parkinson's disease: case reportKarl Strecker, Jürgen Meixensberger, Johannes Schwarz, et al.Neuropharmacology|November 7, 2006
Auto-modulation of neuroactive steroids on GABA A receptors: a novel pharmacological effectFlorian Wegner, Cornelia Rassler, Clemens Allgaier, et al.Scientific Reports|August 23, 2023
Artificial dielectric beam-scanning prism for the terahertz regionKarl Strecker, Matthew Otto, Masaya Nagai, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|May 10, 2012
The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient miceKarl Strecker, Michael Adamaszek, Sven Ohm, et al.Stereotactic and Functional Neurosurgery|October 11, 2013
Implementing conventional Zamorano Dujovny frames versus individually manufactured microTargeting platforms--a comparative study on deep brain stimulation in Parkinson patientsDirk Winkler, Niels Hammer, Christian Oehlwein, et al.Social Cognitive and Affective Neuroscience|September 8, 2012
An ERP study of vocal emotion processing in asymmetric Parkinson's diseasePatricia Garrido-Vásquez, Marc D Pell, Silke Paulmann, et al.Plos One|March 26, 2014
Adaptive gene regulation in the Striatum of RGS9-deficient miceKathy Busse, Rainer Strotmann, Karl Strecker, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|August 31, 2010
Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trialMartin Wolz, Matthias Löhle, Karl Strecker, et al.Pageof 2